Legend Biotech CEO Ying Huang resigns; interim named

Legend Biotech Corporation disclosed that Chief Executive Officer Ying Huang resigned from his roles as CEO and board member, effective July 24, 2026.

Rhea-AI Filing Summary

Legend Biotech Corporation disclosed that Chief Executive Officer Ying Huang resigned from his roles as CEO and board member, effective July 24, 2026. He is expected to continue as an advisor through August to support a smooth transition, and the resignation is stated not to result from any disagreement regarding operations, policies, practices, financial statements, or internal controls over financial reporting.

On July 23, 2026, the board appointed Alan Bash as Interim Chief Executive Officer and interim principal executive officer, effective as of the same effective date. Bash has led CARVYKTI as President since October 2024 and previously held senior roles at ZielBio, Checkmate Pharmaceuticals, and Bristol Myers Squibb. The company notes there is no arrangement or understanding under which he was selected, no related party transactions with him requiring disclosure, and no family relationships with current directors or executive officers.

Positive

• None.

Negative

• CEO Ying Huang resigned as chief executive officer and director, effective July 24, 2026, creating a leadership transition at the top of the company.

Key Figures

CEO resignation effective date: July 24, 2026 Interim CEO appointment decision date: July 23, 2026 Advisory period for Ying Huang: August +3 more

6 metrics

CEO resignation effective date July 24, 2026 Effective Date of Ying Huang’s resignation as Chief Executive Officer and board member

Interim CEO appointment decision date July 23, 2026 Date on which the board appointed Alan Bash as Interim CEO and interim principal executive officer

Advisory period for Ying Huang August Dr. Huang is expected to continue as an advisor to the company through August

Service at Bristol Myers Squibb 1999 to 2022 Period during which Alan Bash held various roles of increasing responsibility at Bristol Myers Squibb

Form F-3 registration numbers 333-278050 and 333-257625 Registration statements into which this report is incorporated by reference

Form S-8 registration numbers 333-239478 and 333-283217 Employee benefit plan registration statements referenced for incorporation

Key Terms

principal executive officer, related party transactions, internal controls over financial reporting, registration statements, +1 more

5 terms

principal executive officer regulatory

"designated him as the Company’s interim principal executive officer"

The principal executive officer is the highest-ranking manager who leads a company’s overall strategy, operations and public communication—often acting like the captain of a ship who sets direction and makes final calls. Investors watch this person because their decisions, credibility and ability to deliver results shape company performance, risk and market confidence, and changes in that role can directly affect stock value and corporate accountability.

related party transactions regulatory

"There are no related party transactions between Mr. Bash and the Company"

Transactions between a company and people or entities that have close ties to it—such as executives, board members, major shareholders, family members, or related companies—where the parties are not independent. These deals matter to investors because they can create conflicts of interest or hide favorable terms that distort a company’s true profits and risks; think of it like a business buying or selling to a family member instead of using the open market, which can lead to biased prices or undisclosed obligations.

internal controls over financial reporting regulatory

"the Company’s financial statements or internal controls over financial reporting"

Internal controls over financial reporting are the policies, procedures and checks a company uses to make sure its accounting and financial statements are accurate, complete and free from significant error or fraud. They matter to investors because strong controls lower the risk of misleading results or surprise restatements—think of them as a quality checkpoint on a factory line that helps prevent costly defects that could damage a company’s value and reputation.

registration statements regulatory

"incorporated herein by reference in the registration statements of Legend Biotech"

Registration statements are detailed documents companies file with securities regulators when they plan to offer shares or other securities to the public. They act like a recipe and instruction manual, listing a company’s business, finances, management, risks and how the offering will work, so investors can judge value and potential downsides. For investors, these filings provide the official, legally required facts needed to make informed decisions and spot warning signs.

Form S-8 regulatory

"registration statements on Form F-3 ... and Form S-8 (No. 333-239478 and 333-283217)"

A Form S-8 is a U.S. Securities and Exchange Commission registration that lets a public company set aside shares for employee benefit plans and stock-based compensation. Think of it as opening a dedicated account that authorizes the company to issue or reserve stock for workers and directors; it matters to investors because it enables share dilution when those awards are granted or exercised and signals how management is compensated and incentivized.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What leadership change did Legend Biotech (LEGN) announce in July 2026?

Legend Biotech announced that Chief Executive Officer Ying Huang resigned from his roles as CEO and board member, effective July 24, 2026. The board appointed Alan Bash as Interim CEO and interim principal executive officer effective as of the same date.

When does Ying Huang’s resignation as Legend Biotech (LEGN) CEO become effective?

Ying Huang’s resignation as Legend Biotech’s Chief Executive Officer and director is effective July 24, 2026. He has notified the board and is expected to continue as an advisor through August to help ensure a smooth transition of his duties.

Who is serving as Legend Biotech (LEGN)’s Interim CEO and what is his background?

Alan Bash has been appointed Interim Chief Executive Officer and interim principal executive officer. He has served as President of CARVYKTI since October 2024 and previously led ZielBio and Checkmate Pharmaceuticals, after various roles at Bristol Myers Squibb from 1999 to 2022.

Did Ying Huang resign from Legend Biotech (LEGN) because of disagreements with the company?

Legend Biotech states that Ying Huang’s resignation was not the result of any disagreement regarding the company’s operations, policies, practices, financial statements, or internal controls over financial reporting, indicating the departure is not tied to a reported dispute on these matters.

Will Ying Huang continue working with Legend Biotech (LEGN) after stepping down as CEO?

Yes. Legend Biotech expects Dr. Huang to continue as an advisor through August after his July 24, 2026 resignation as CEO and director, with the advisory role intended to support continuity and a smooth transition of leadership responsibilities.

Are there any related party transactions involving interim CEO Alan Bash at Legend Biotech (LEGN)?

Legend Biotech reports that there are no related party transactions between Interim CEO Alan Bash and the company requiring disclosure, and notes no family relationship between Bash and any of the company’s directors or other executive officers.

Has Legend Biotech (LEGN) begun searching for a permanent Chief Executive Officer?

Yes. Following Ying Huang’s resignation, the company states it has initiated a search for its next Chief Executive Officer. During this period, Alan Bash will serve as Interim CEO and interim principal executive officer effective as of July 24, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/27/2026 - 06:03 AM Accepted by SEC EDGAR 07/27/2026 - 06:02 AM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

Date of Report: July 27, 2026

Commission File Number: 001-39307

Legend Biotech Corporation

(Exact Name of Registrant as Specified in its Charter)

77 Corporate Drive

Bridgewater, New Jersey 08807

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒    Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

Resignation of Ying Huang as Chief Executive Officer

On July 22, 2026, Ying Huang notified the Board of Directors (the “Board”) of Legend Biotech Corporation (the “Company”) of his resignation from his position as the Company’s Chief Executive Officer and as a member of the Board, effective as of July 24, 2026 (the “Effective Date”). The Company expects that Dr. Huang will continue as an advisor to the Company through August to ensure a smooth transition of his duties. Dr. Huang’s resignation was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices or the Company’s financial statements or internal controls over financial reporting. The Company has initiated a search for the Company’s next Chief Executive Officer.

Appointment of Alan Bash as Interim Chief Executive Officer

On July 23, 2026, the Board appointed Alan Bash as the Company’s Interim Chief Executive Officer and designated him as the Company’s interim principal executive officer, each effective as of the Effective Date.

Mr. Bash has served as the Company’s President of CARVYKTI since October 2024. Prior to joining the Company, Mr. Bash was the Chief Executive Officer of ZielBio, Inc. from December 2022 to October 2024 and the President and Chief Executive Officer of Checkmate Pharmaceuticals from March 2022 to June 2022. Prior to that, Mr. Bash served in various roles of increasing responsibility at Bristol Myers Squibb from 1999 to 2022. Mr. Bash earned his B.A. from Georgetown University and his MBA from Columbia Business School.

There is no arrangement or understanding between Mr. Bash and any other person pursuant to which he was selected as an officer of the Company. There are no related party transactions between Mr. Bash and the Company that would require disclosure, and there is no family relationship between Mr. Bash and any of the Company’s directors or other executive officers.

This report on Form 6-K is hereby incorporated herein by reference in the registration statements of Legend Biotech on Form F-3 (Nos. 333-278050 and 333-257625) and Form S-8 (No. 333-239478 and 333-283217), to the extent not superseded by documents or reports subsequently filed.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

				LEGEND BIOTECH CORPORATION (Registrant)
July 27, 2026				By:		/s/ Carlos Santos Garcia
						Carlos Santos Garcia
						Chief Financial Officer